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Abstract 
Background: Membranous Nephropathy (MN) is a common cause of nephrotic syndrome in 
adults. Previous genome-wide association studies (GWAS) of 300,000 genotyped variants 
identified MN-associated loci at HLA-DQA1 and PLA2R1.  
Methods: We used a combined approach of genotype imputation, GWAS, HLA imputation and 
extension to other etiologies of chronic kidney disease (CKD) to investigate genetic MN risk 
variants more comprehensively.   
GWAS using 9 million high-quality imputed genotypes and classical HLA alleles were conducted 
for 323 MN European-ancestry cases and 345 controls. Additionally, 4,960 patients with 
different CKD etiologies in the German Chronic Kidney Disease (GCKD) study were genotyped 
for risk variants at HLA-DQA1 and PLA2R1. 
Results: In GWAS, known variants (rs9272729, HLA-DQA1, OR=7.3 per risk allele, p=6.7*10-27 
and rs17830558, PLA2R1, OR=2.2, p=1.9*10-8) were significantly associated with MN. No novel 
signals emerged in GWAS of X-chromosomal variants or in sex-specific analyses. Classical HLA 
alleles (DRB1*0301-DQA1*0501-DQB1*0201 haplotype) were associated with MN but provided 
little additional information beyond rs9272729.  
Associations replicated in 137 GCKD patients with MN (HLA-DQA1: p=6.4*10-24; PLA2R1: 
p=5.0*10-4). MN risk increased steeply for patients with high-risk genotype combinations 
(OR>79). While genetic variation in PLA2R1 exclusively associated with MN across 19 CKD 
etiologies, the HLA-DQA1 risk allele was also associated with lupus nephritis (p=2.8*10-6), type I 
diabetic nephropathy (p=6.9*10-5) and focal segmental glomerulosclerosis (p=5.1*10-5), but not 
with IgA nephropathy. 
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Conclusions: PLA2R1 and HLA-DQA1 are the predominant risk loci for MN detected by GWAS. 
While HLA-DQA1 risk variants show association with other CKD etiologies, PLA2R1 variants are 
specific to MN. 
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Summary 
PLA2R1 and HLA-DQA1 are the predominant risk loci for MN. Common variants in these two loci 
give rise to rare high-risk genotype combinations; the associated MN risk is of a magnitude 
otherwise only observed for single-gene disorders. The risk allele at HLA-DQA1, but not in 
PLA2R1, is also associated with CKD resulting from type I diabetes, SLE and FSGS, but not from 
IgA nephropathy, another auto-immune kidney disease.  
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Introduction 
Membranous Nephropathy (MN) is one of the most common causes of the nephrotic syndrome 
in adults.1, 2 It is considered an immune complex-mediated disease, with sub-epithelial deposits 
of immune complexes detectable using immunofluorescence or electron microscopy. In some 
patients, MN is secondary and consequential to tumors, infections or exposure to 
environmental factors. The majority of patients, however, suffer from so-called primary MN, 
termed “idiopathic” (IMN) until the recent recognition as an autoimmune disease.  
 A genetic component to MN has long been suspected based on familial clustering.3 The 
involvement of a risk allele at the HLA locus, and more specifically of DQA1, has already been 
proposed in MN pathogenesis in the late 1980’s.4 Additional insights into MN pathophysiology 
from animal experiments showed that immune complex formation can result from interactions 
of antibodies with a local antigen on podocytes.1 In humans, the M-type phospholipase A2 
receptor protein at the podocyte surface was identified as the major autoantigen in patients 
with MN.5 More recently thrombospondin type-1 domain-containing 7A (THSD7A) was 
identified as another autoantigen in phospholipase A2 receptor antibody negative patients with 
MN.6 
 Genome-wide association studies (GWAS) can be used to evaluate the association 
between genome-wide genetic markers and a disease in a comprehensive and unbiased way. 
The first meta-analysis of GWAS of MN identified strong associations between MN and single 
nucleotide polymorphisms (SNPs) at the HLA-DQA1 locus and in PLA2R1, encoding the M-type 
phospholipase A2 receptor.7 This study did not only provide evidence for the influence of an 
individual’s genetic make-up in shaping the interaction between adaptive immune system and 
auto-antigens, but also provided striking evidence that the combination of risk alleles at only 
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two genetic loci was associated with large increases in disease risk of a magnitude that is 
typically only observed for single gene disorders.  
However, previous GWAS of MN have only evaluated a limited set of approximately 
300,000 genotyped genetic variants and have not used imputation methods8, 9 to increase 
marker coverage or to obtain information on classical HLA alleles.10 Genotype imputation can 
increase statistical power to detect genetic associations.9 Imputation to the 1000 Genomes 
reference panel in previous studies has led to the identification of additional risk loci that were 
missed in previous association studies of at least equal size, for example for body mass index, 
fasting glucose or coronary artery disease.11, 12 In addition, GWAS conditioning on the associated 
index variants can lead to the identification of secondary independent signals in associated 
regions.13 Moreover, although MN shows a male predilection,1 previous studies have combined 
both sexes to evaluate genetic associations and only studied autosomes. Finally, it has not been 
studied systematically whether the previously identified genetic risk variants in the HLA locus 
and PLA2R1 confer risk that is specific to MN, or if they also increase risk for other etiologies of 
chronic kidney disease (CKD). The present study therefore aimed to address these important 
gaps.  
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Subjects and Methods 
For the GWAS of MN, DNA samples from 336 British MN cases that provided written informed 
consent were collected by the MRC/Kidney Research UK National DNA Bank for 
Glomerulonephritis and racially matched to samples from 349 control subjects of the 1958 UK 
Birth Control study (http://www.b58cgene.sgul.ac.uk). Study protocol and sample 
characteristics have been described previously.7 On average, MN patients were of 52.5 (±13.3) 
years old at the time of diagnosis, and 69% of them were men. 
For replication and characterization, we examined patients taking part in the German 
Chronic Kidney Disease (GCKD) study, a prospective observational study of patients with CKD 
with either eGFR between 30 and 60 mL/min/1.73m² or overt proteinuria (albumin-to-
creatinine ratio > 300mg/g or protein-to-creatinine ratio > 500 mg/g) upon study inclusion.14 
The study was approved by local review boards at each participating academic institution and is 
described in detail elsewhere.15 Briefly, 5,217 patients who gave their written informed consent 
were enrolled into the study between 2010 and 2012. The patients’ long-term treating 
nephrologists were asked to select the leading i.e. primary cause of CKD for each patient. For 
disease categories in which biopsy was not performed for the majority of patients, such as 
diabetic or hypertensive kidney disease, diagnosis was established by the nephrologists based 
on clinical grounds. The assignment of these causes was consistent with comorbidities reported 
by the patients as well as with the presence of elevated biomarkers at the study visit (elevated 
hemoglobin A1c and blood pressure) and the intake of anti-diabetic and anti-hypertensive 
medication, respectively. All patients were of Caucasian ancestry, and 60% were men. At the 
time of entry, patients were on average 60.0 (±12.0) years old and had CKD of various 
etiologies.16 MN as the leading cause of CKD was identified in 151 of 5,217 patients, 144 of 
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whom had a biopsy to confirm the diagnosis (80% men). In addition, other specific, leading 
causes of CKD that comprised at least 40 patients were evaluated as well as one smaller group 
of patients with rapidly progressive glomerulonephritis (pauci-immune; n=28). Analyses were 
restricted to patients with a biopsy-proven diagnosis when the proportion of patients with 
biopsies in a given group was >70%. Information on steroid sensitivity of FSGS was not available. 
As a control group, genotypes from 379 individuals (47% men) comprising the European 
subgroup of the 1000 Genomes project were used (http://www.1000genomes.org/home; phase 
1, release v3, panel EUR). Data were downloaded from 
http://www.sph.umich.edu/csg/abecasis/MaCH/download/1000G.2012-03-14.html, and 
genotypes for selected SNPs were subsequently extracted. 
Because of the complexity, detailed information on genotyping, quality control and 
imputation as well as on statistical analyses can be found in Complete Methods 
(Supplementary Text 1 and 2).  
In brief, GWAS study samples were genotyped using HumanCNV370-Quad SNP chip or 
the HumanHap300 SNP chip. After stringent quality control using Plink and Eigensoft, the 
cleaned data set comprised 282,462 SNPs of 323 cases and 345 controls.17, 18 Subsequently, 
genotype imputation was carried out using Shapeit and Impute2.19, 20  Data from the 1000 
Genomes Project (phase 1, release v3, panel ALL) served as reference panel. The final data set 
contains 8.9 million SNPs of high quality. In the GCKD study, genotyping of index variants was 
carried out using an Agena (formerly Sequenom) iPLEX assay (PLA2R1) and using a Life 
Technologies TaqMan assay (HLA-DQA1) with call rates of 99% and genotype concordance of 
100% among duplicate samples. 
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Association tests relating MN case status to autosomal genetic variants were carried out 
using genotype probabilities (dosages) and an additive genetic model with the software SNPtest 
version 2.4.1.21 The first five principle components were included as covariates. Statistical 
significance was set to the standard threshold of 5.0*10-8. Independent replication was defined 
as a direction-consistent 2-sided p-value <0.05 (equivalent to 1-sided test). Inverse-variance 
weighted, fixed effect meta-analysis was conducted to pool results.  
In GCKD, genotype information was also evaluated for association with CKD of 17 
additional specific etiologies as well as using all GCKD participants as a CKD case group, all in 
comparison to the 1000 Genomes control group. The statistical significance cutoff for these 
analyses was set to 2.6*10-3. 
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Results 
Genome-Wide Association Studies of MN 
We carried out a GWAS among 323 MN cases and 345 controls of European ancestry using 
imputed genotypes as illustrated in the detailed analysis plan in Supplementary Figure 1. GWAS 
results did not show any evidence for inflation of the test statistics, indicating no systematic 
biases (Quantile-Quantile plot, Supplementary Figure 2). The two previously reported genetic 
regions, PLA2R1 and HLA-DQA1,7 contained SNPs associated with MN at genome-wide 
significance (Figure 1). The index SNPs at the two loci used in subsequent analyses were 
rs9272729 in HLA-DQA1 (p-value=6.7*10-27) and rs17830558 in PLA2R1 (p-value=1.9*10-8, Table 
1). In both instances, the index SNPs were imputed with high imputation quality and were 
correlated with the previously published SNPs (Table 1). Supplementary Figures 3a and 3b 
display the two associated regions in more detail. The previously described extensive linkage 
disequilibrium (LD) in the HLA region is evident, extending several hundred kilobases around 
HLA-DQA1 and including other HLA genes such as HLA-DQB1, HLA-DRB1, HLA-DRB6, and HLA-
DRB5.  
No additional loci on the autosomes or the X chromosome contained SNPs associated 
with MN at genome-wide significance. Supplementary Table 1 contains all SNPs on autosomes 
and chromosome X with minor allele frequency (MAF) >5% and corrected p-value<10-5. 
Secondary Analyses 
To further examine the genetic architecture of MN, several secondary analyses were carried 
out: first, because of the observed male predilection, additional GWAS were conducted 
separately for men (222 cases, 106 controls) and women (101 cases, 239 controls). These 
analyses were carried out because of the strong observed male predilection for MN, although 
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the smaller sample sizes limit statistical power. No additional signals of genome-wide 
significance were identified in either men or women (data not shown). Second, we evaluated 
whether a recessive model instead of an additive model, which is typically used in discovery 
GWAS, better fit the data. Consistent with lower statistical power of a recessive model, p-values 
were larger than those obtained from the additive model for both PLA2R1 and HLA-DQA1. No 
other genomic regions contained significantly associated markers (data not shown). 
We evaluated the identified regions containing PLA2R1 and HLA-DQA1 more closely in 
order to assess the presence of more than one independent signal of genome-wide significance. 
After conditioning on the index SNP of the corresponding region, no additional SNP across the 
respective chromosome was associated with MN at genome-wide significance. Thus, based on 
the variants assessed in this study, there was no evidence of multiple common independent 
variants in the known regions that contributed to the observed associations at genome-wide 
significance. 
Finally, a very recent publication by Gbadegesin and colleagues reported on the 
association of a HLA-DQA1 risk allele and steroid-sensitive nephrotic syndrome (SSNS) in 
children.22 We therefore assessed whether the reported index variant, rs1129740, was also 
associated with MN in our genome-wide data. The reported risk allele for SSNS, the major A 
allele, was significantly associated with MN risk in our data (OR=2.48, 95% CI 1.81-3.40, p-
value=4.45*10-9). The OR for MN was similar to the one published for SSNS. The SSNS index 
variant rs1129740 was correlated with the MN index SNP evaluated in this study, rs9272729 
(r2=0.19, D’=1, based on the MN GWAS data). Besides MN, the SSNS risk allele at rs1129740 was 
also nominally associated with minimal change disease (OR=1.6, 95% CI 1.1-2.5, p-value=0.014) 
and FSGS (OR=1.5, 95% CI 1.2-2.0, p-value=0.002) in the GCKD study.  
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Replication and Interactions 
Replication of SNP Associations and Meta-Analysis 
We assessed evidence for replication of the association at the index variants in PLA2R1 and HLA-
DQA1 in 137 participants of the GCKD study with biopsy-proven MN and 379 ethnically matched 
controls (see Concise Methods). Both index SNPs were associated with MN after correction for 
multiple testing in this replication sample (Table 1, p-value=5.0*10-4 for PLA2R1 and 6.4*10-24 
for HLA-DQA1). The odds ratios for MN after meta-analysis of the discovery and replication 
samples were 1.87 (95% CI 1.54-2.28) for PLA2R1 and 7.07 (95% CI 5.28-9.47) for HLA-DQA1 for 
each additional copy of a risk allele.  
Combined Allelic Effects and Interactions 
Figure 2 presents the association with MN for the combination of risk alleles at PLA2R1 and 
HLA-DQA1. The risk for MN increased dramatically with a higher number of risk alleles: almost 
all persons carrying two risk alleles at HLA-DQA1 were affected with MN (14 of 16, 88%), and all 
three individuals who carried two risk alleles at both loci were affected with MN (so that no risk 
estimates could be provided, see arrow in Figure). The second highest risk of MN was observed 
for individuals carrying two risk alleles at HLA-DQA1 and one risk allele at PLA2R1. Compared to 
individuals who did not carry any risk alleles, their MN risk was increased almost 80-fold (OR 
79.4, p-value=7.1*10-5). Supplementary Table 2 displays case and control numbers for all risk 
categories, and - to obtain more stable numerical estimates - the corresponding results when 
combining individuals carrying one or two risk alleles at the HLA-DQA1 locus into a single 
category.  
 Evidence for statistical interaction between the two index variants at PLA2R1 and HLA-
DQA1 was assessed by simultaneous inclusion of the variants as well as of an interaction term 
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into the regression model (see Concise Methods). Compared to a model containing both 
variants but no interaction term, the inclusion of the interaction term lead to a decrease of 
Akaike’s information criterion (AIC) from 491.9 to 487.2, which was statistically significant (LR-
test p-value: 0.009). The odds ratio of the interaction term in this model was 2.20 (p-
value=0.01), which together with the lower AIC supports that the combination of risk alleles 
increases MN risk to a stronger degree than expected based on the effect of the individual risk 
alleles at the two loci by themselves. 
Characterization across CKD Etiologies Reveals Shared Associations at HLA-DQA1 
Subsequently, we evaluated whether the association at PLA2R1 and HLA-DQA1 is specific to 
MN, or whether it extends to additional etiologies of CKD in the large GCKD study, which 
collected information on the underlying cause of CKD (see Concise Methods). Table 2 shows the 
association of the two index variants with CKD defined based on estimated glomerular filtration 
rate (eGFR) and/or albuminuria, as well as with 17 specific etiologies of CKD. PLA2R1 was only 
associated with MN but no other CKD etiology after correction for multiple testing. Conversely, 
a significant association of the HLA-DQA1 risk variant was observed not only with MN, but also 
with lupus nephritis (p-value=2.8*10-6), CKD in type 1 diabetes mellitus (p-value=6.9*10-5), and 
focal segmental glomerulosclerosis (FSGS, p-value=5.1*10-5). The latter association with FSGS 
remained significant even after the exclusion of 8 patients with HIV and hepatitis, potential 
causes of and thus potentially suffering from secondary FSGS (p-value=2.3*10-5). The observed 
association with CKD (p-value=1.3*10-3) was mainly due to the inclusion of patients with MN, 
lupus nephritis, type 1 diabetes mellitus and FSGS.  
Associations with Classical HLA Alleles 
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Lastly, we attempted to assess whether MN showed stronger associations with carrier status of 
classical HLA alleles than with the index variant identified in the GWAS, and thus imputed 
classical HLA alleles from the genotyped SNPs in the discovery sample (see Concise Methods). 
MN was significantly associated with seven of the classical HLA alleles at genome-wide 
significance (Table 3). Whereas the lowest p-value was observed for HLA-DRB1*0301 carrier 
status (OR 6.15, p-value=1.6*10-28), HLA-DQA1*0501 conferred the largest risk (OR 6.23, p-
value=1.4*10-27). Carrier status at these two HLA alleles was almost perfectly correlated 
(Spearman r=0.995), indicating a long shared risk haplotype, to which also HLA-DQB1*0201 
belongs (Spearman correlation with HLA-DQA1*0501 r=1). Supplementary Table 3 presents the 
associations of all imputed common HLA alleles (MAF>5%) with MN. 
 Using the classical HLA allele HLA-DQA1*0501 as a proxy for this risk haplotype, we 
assessed whether the index SNP at HLA-DQA1 in the discovery GWAS, rs9272729, provided 
independent information. Individually, the association of rs9272729 with MN was of similar 
magnitude as the association of HLA-DQA1*0501 with MN: OR 6.51 (p-value=7.16*10-19) for the 
SNP vs. OR 5.87 (p-value=1.25*10-18) for the HLA allele among individuals with both types of 
information available. Upon simultaneous inclusion of rs9272729 and HLA-DQA1*0501 into the 
model, the effects of both variables were attenuated but still significant. There was a significant 
improvement of model fit (likelihood ratio test p-value=0.02), suggesting that the SNP captures 
most of the information but other variants in the genomic region and/or classical HLA alleles 
may still add some additional information. 
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Discussion 
In this first GWAS of MN using imputed genotypes, we confirm the predominant importance of 
risk alleles at PLA2R1 and HLA-DQA1 in modulating MN risk. With the available number of cases, 
we did not find evidence for additional or independent common risk alleles or of sex-specific 
risk loci. While we found that genetic variation in PLA2R1 exclusively associated with MN across 
a wide range of CKD etiologies studied, the risk allele at HLA-DQA1 was also associated with 
higher odds of a number of other auto-immunity associated kidney diseases – lupus nephritis, 
type I diabetic nephropathy and FSGS - but not with IgA nephropathy. 
 In accordance with other studies,23 our results from the GCKD study confirmed the 
association between MN and previously reported risk variants or their proxies in PLA2R1 and 
HLA-DQA1. In addition, in our GWAS of high coverage, we did not identify additional common 
risk variants of similar importance. While imputation to the 1000 Genomes reference panel has 
led to the identification of additional risk loci missed in earlier studies of similar size for a variety 
of traits and diseases,11, 12 this was not the case for MN. Our study therefore highlights the oligo-
genic architecture of MN, informs future studies to detect genes encoding for additional 
antigens, and confirms PLA2R1 as a risk locus of major and specific importance. This is 
consistent with the presence of anti-PLA2R1 antibodies in about 70-80% of MN patients.1 In the 
independent GCKD study, we also confirmed the large increase in MN risk conferred by the 
combination of risk variants at PLA2R1 and HLA-DQA1, as well as a statistical interaction 
between the risk variants at both loci.24 In fact, all GCKD patients who were homozygous for the 
risk alleles at both loci were affected with MN, as were the great majority of persons 
homozygous for the risk allele at HLA-DQA1 and heterozygous at PLA2R1. There are several 
potential explanations for the higher proportion of MN patients among carriers of high-risk 
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genotype combinations in the GCKD study compared to the initial study,7 including random 
fluctuations due to small numbers, differences in the prevalence of contributing environmental 
triggers, and recruitment of patients under nephrological care with reduced eGFR into the GCKD 
study, which may enrich for MN patients with advanced disease and high-risk genotypes. Only 
long-term prospective studies, if not lifetime studies, will be able to answer how many 
individuals carrying high-risk genotype combinations will not develop MN over their life course. 
Likewise, conclusive answers relating to long-term outcomes require standardized observational 
studies that follow patients for at least 10 years and/or until death while collecting information 
on immunosuppressive treatments and other comorbidities. 
Our imputation of classical HLA alleles revealed the strongest associations with HLA-
DQA1*0501, HLA-DRB1*0301, and HLA-DQB1*0201. The almost perfect correlation between 
these alleles implicates one long shared MN risk haplotype on which these alleles reside, 
DRB1*0301-DQA1*0501-DQB1*0201. This is supported by the reported finding that circulating 
anti-PLA2R1 antibody levels in MN cases are linked to the number of alleles of DQA1*0501 and 
DQB1*0201.25 Therefore, although we refer to the HLA risk allele as the HLA-DQA1 locus, the 
underlying causal variant could also be situated in HLA-DQB1 or HLA-DRB1. Given the large 
inter-individual genetic variability of the HLA region, it is noteworthy that our analyses suggest 
that most of the strong association with MN at this locus can be captured by knowledge of the 
genotype at a single common SNP in the region, which may have clinical implications for risk 
prediction. Our observations are consistent with a relatively common genetic predisposition 
which controls antigen processing and/or presentation, that only together with additional 
factors such as the presence of specific auto-antigens processed peptides – from, for example, 
specific forms of PLA2R1 for MN - and/or certain environmental triggers gives rise to a specific 
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autoantibody to cause disease.7 In support, the DRB1*0301-DQA1*0501-DQB1*0201 haplotype 
has also been described to increase the risk for other common auto-immune diseases including 
type I diabetes,26 lupus erythematosus (SLE),27 celiac disease,28 and thyroid disease.29  
Our data indicate that this observation may extend to SSNS.  As SSNS is commonly 
observed in children, it was not among the etiologies that could be evaluated in the GCKD study. 
However, the association of the reported SSNS risk allele with MN risk in our GWAS and the high 
correlation of the risk allele of the reported SSNS variant and the risk allele of the MN index 
variant in our data suggests that the genetic predisposition at the HLA-DQA1 locus shares at 
least some degree of overlap between SSNS and MN. The results from the GCKD study further 
suggest that the shared susceptibility between the SSNS variant extends to an association with 
minimal change disease and FSGS in adulthood. In contrast, there was no statistically significant 
association between the HLA-DQA1 risk allele for MN and IgA nephropathy, another auto-
immune kidney disease. This is consistent with the fact that previous GWAS of IgA nephropathy 
have highlighted other associated alleles in the HLA-DQA1 region.30  
 While genetic variants in the HLA-DQA1 locus were associated with a variety of 
underlying causes of CKD, those in PLA2R1 uniquely associated with MN across almost 20 
different etiologies of CKD. The genetic associations between HLA risk alleles and nephropathy 
resulting from SLE or type I diabetes are biologically plausible, given the shared genetic 
susceptibility to these auto-immune diseases. Because of the case-only design of the GCKD 
study, we could not specifically assess whether the HLA risk allele increases risk for nephropathy 
in the setting of type I diabetes and SLE, or whether the observed associations are due to an 
association with the primary cause of CKD. The mechanisms underlying the observed 
association with FSGS need further study to delineate whether they are indicative of a common 
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mechanism resulting in FSGS-defining features in the biopsies, or whether some of the cases in 
whom the primary CKD etiology was assigned as FSGS may in fact have additional specific 
causes contributing to their nephropathy such as SLE. Moreover, we cannot exclude the 
possibility that – although intended – not all patients with FSGS may have the primary disease 
form. Although not significant after correction for multiple testing, the risk allele at HLA-DQA1 
also more than doubled the odds of membranoproliferative GN. If this association could be 
shown in a larger cohort of patients, itThis could be indicative of an auto-immune component 
specific to rapidly progressingmembranoproliferative GN, or represent cases of secondary 
membranoproliferative GN, such as those observed in SLE.  
Our approach highlights the power of collecting detailed information on kidney disease 
phenotypes, as the specific evaluation of associations across disease subtypes can reveal 
significant associations that would be missed in genome-wide association studies of these CKD 
etiologies. A similar observation has been made for the APOL1 risk alleles, where associations 
with FSGS and nondiabetic end-stage renal disease - originally identified using genome-wide 
approaches - were shown to extend to HIV-associated nephropathy without conducting a 
separate genome-wide genetic screen.31, 32  
Strengths of our study include the availability of high-coverage genome-wide data as 
well as the variety of CKD etiologies in the GCKD study that allowed us to evaluate the presence 
of novel associations, carefully characterize known associations and identify a shared genetic 
predisposition to several auto-immune kidney diseases. Our study also has potential limitations: 
genotypes were generated on different platforms, which we addressed through careful data 
cleaning and combined imputation based on a common SNP set. Although – for a rare disease 
such as MN - we studied a sizeable number of cases, our study may still be underpowered to 
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identify associations with rare alleles or alleles conferring moderate or small increases in risk. 
For example, we did not find evidence for association between THSD7A variant and MN, which 
may not be surprising given the fact that this autoantigen has only been described in a minority 
of patients. In addition, because we evaluated chip-based and imputed genotypes, there may be 
rare risk variants that can only be discovered through sequencing-based approaches. At least for 
PLA2R1, however, targeted re-sequencing of the exons and canonical splice sites did not yield 
rare variants that could explain the observed association.33 In our study of prevalent MN cases, 
we did not have information on PLA2R1-antibody concentrations and could therefore not 
investigate antibody-negative patients separately. In any case, statistical power to detect novel 
associated loci among antibody-negative patients in the current study, assuming 20% antibody-
negative patients among the cases, would have been <30% even for very common alleles. The 
assembly of larger collectives of MN patients with antibody-status and genome-wide genotypes 
is therefore an important future endeavor. Likewise, larger collectives of patients with other 
primary forms of specific CKD etiologies such as FSGS are needed to confirm our findings or to 
establish statistical significance such as with membranoproliferative GN. Although in the GCKD 
study the patients’ treating nephrologists were asked to identify the leading cause of CKD, 
misclassification can occur especially for leading causes of CKD that are typically not confirmed 
by kidney biopsy or for which no specific diagnostic criteria are available. Finally, as in all 
association studies, we cannot directly pinpoint causal variants, but associated variants may still 
be valuable for risk stratification.  
In conclusion, PLA2R1 and HLA-DQA1 are the predominant risk loci for MN. Common 
variants in these two loci give rise to rare high-risk genotype combinations, which associate with 
disease risk of a magnitude otherwise observed for single gene disorders. The risk allele at HLA-
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DQA1, but not in PLA2R1, is also associated with nephropathy resulting from type I diabetes, SLE 
and FSGS, but not with IgA nephropathy, another auto-immune kidney disease. Future studies 
including those in PLA2R1-antibody negative patients and sequencing-based association studies 
should evaluate the presence of additional rare genetic risk variants for MN.  
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Table 1: Replicated SNPs Associated with MN at Genome-Wide Significance 
 
gene PLA2R1 HLA-DQA1 
SNP-ID rs17830558† rs9272729‡ 
chr:pos (hg19) chr2:160878364 chr6:32609594 
function intronic intronic 
imputed 
(quality) 
yes 
(0.938) 
yes 
(0.901) 
A1/A2 T/G A/G 
Discovery analysis 
Allele frequency A1 0.54 0.24 
OR 2.16 7.29 
95% CI* 1.65-2.82 4.81-11.04 
p-value* 1.9*10-8 6.7*10-27 
Replication analysis 
Allele frequency A1 0.49 0.16 
OR 1.63 6.86 
95% CI 1.23-2.15 4.55-10.34 
p-value 5.0*10-4 6.4*10-24 
Meta-analysis 
Allele frequency A1 0.52 0.20 
OR 1.87 7.07 
95% CI 1.54-2.28 5.28-9.47 
p-value 3.7*10-10 2.1*10-39 
OR: odds ratio; CI: confidence interval; * GC-corrected values  
† SNP rs17830558 was used in all subsequent analyses of replication and meta-analysis as proxy for rs17830307  
that showed the lowest p-value in the association analysis (results can be found in Supplementary Table 1)  
‡ In GCKD, instead the proxy rs2187668 was genotyped  
Pairwise correlations (within our data of 668 subjects) of rs9272729 and previously reported rs2187668: r²=0.87;  
of rs17830558 and previously reported rs4664308, r²=0.40. 
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Table 2: Association of Replicated SNPs with Different CKD Etiologies in the GCKD Study 
CKD etiology (leading cause) n 
% biopsy 
proven 
rs17830558  (PLA2R1) rs9272729  (HLA-DQA1)#    
OR 95% CI p-value OR 95% CI p-value 
MN* 137 100 1.63 1.23-2.15 5.0*10-4 6.86 4.55-10.34 6.4*10-24 
lupus nephritis* 104 100 1.10 0.82-1.47 5.2*10-1 3.00 1.90-4.72 2.8*10-6 
diabetes mellitus, type 1 89 3.4 0.76 0.55-1.05 9.2*10-2 2.69 1.67-4.34 6.9*10-5 
focal segmental glomerulosclerosis* 139 100 0.87 0.66-1.14 3.1*10-1 2.36 1.56-3.57 5.1*10-5 
membranoproliferative GN* 36 100 1.36 0.85-2.19 1.9*10-1 2.15 1.10-4.22 3.5*10-2 
minimal change GN* 53 100 1.30 0.87-1.94 2.0*10-1 1.70 0.90-3.22 1.2*10-1 
interstitial nephritis 135 19.3 0.98 0.75-1.29 9.1*10-1 1.56 1.00-2.43 5.3*10-2 
nephrosclerosis 1087 7.9 0.97 0.82-1.15 7.4*10-1 1.47 1.10-1.96 7.8*10-3 
diabetes mellitus, type 2 649 4.2 0.89 0.74-1.07 2.0*10-1 1.38 1.02-1.87 3.3*10-2 
renal artery stenosis 47 0 1.32 0.87-2.00 1.9*10-1 1.29 0.64-2.62 4.9*10-1 
Wegener’s granulomatosis* 77 100 0.93 0.67-1.31 6.9*10-1 1.18 0.66-2.13 5.8*10-1 
IgA nephropathy* 308 100 1.02 0.83-1.25 8.6*10-1 1.14 0.79-1.63 4.8*10-1 
autosomal dominant polycystic kidney disease  170 1.8 1.07 0.83-1.37 6.2*10-1 1.13 0.73-1.77 5.8*10-1 
tumor nephrectomy 61 11.5 0.91 0.63-1.32 6.2*10-1 1.07 0.55-2.08 8.4*10-1 
analgesic nephropathy 52 3.8 1.12 0.76-1.67 5.6*10-1 1.03 0.49-2.16 9.4*10-1 
acute kidney injury 59 10.2 0.90 0.61-1.32 5.9*10-1 1.02 0.50-2.08 9.5*10-1 
micropolyangiitis* 54 100 0.82 0.55-1.22 3.3*10-1 0.52 0.20-1.33 1.4*10-1 
rapidly progressive GN, pauci-immune* 25 100 0.72 0.41-1.29 2.7*10-1 0.45 0.11-1.88 2.2*10-1 
KDIGO-defined CKD (all GCKD participants) 4960 25.8 0.99 0.86-1.15 9.1*10-1 1.50 1.16-1.94 1.3*10-3 
OR: odds ratio; CI: confidence interval; MN: membranous nephropathy; GN: glomerulonephritis; CKD: chronic kidney disease   
P-values that are statistically significant after correction for multiple testing are bolded (p-value<2.6*10-3=0.05/19). 
* Analysis based on patients with biopsy-proven (leading) cause only because proportion of available biopsy results >70%  
# In GCKD, the proxy SNP rs2187668 was genotyped 
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Table 3: Association of Imputed Classical HLA Alleles with MN  
HLA allele MAF OR 95% CI p-value 
DRB1-0301 0.27 6.15 4.27-8.85 1.6*10-28 
DQA1-0501 0.30 6.23 4.29-9.04 1.4*10-27 
DQB1-0201 0.27 5.89 4.11-8.45 1.5*10-27 
B-0801 0.24 4.47 3.16-6.33 7.5*10-20 
DRB3-0100 0.26 3.98 2.83-5.59 1.3*10-17 
DRB3-9901 0.47 0.29 0.21-0.39 1.6*10-17 
C-0701 0.28 2.94 2.14-4.03 2.4*10-12 
MAF: minor allele frequency; OR: odds ratio; CI: confidence interval 
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Figure Legends 
Figure 1:  Results from the GWAS of MN using Imputed Genotype Data (GC-corrected p- 
values, filtered by MAF>10%). 
Figure 2:  Combined Effect of Genetic Risk Variants at Replicated Loci on Risk of MN in the  
GCKD Study. 
  
 31 
Figure 1: Results from the GWAS of MN using Imputed Genotype Data (GC-corrected p-values, 
filtered by MAF>10%). 
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Figure 2: Combined Effect of Genetic Risk Variants at Replicated Loci on Risk of MN in the 
GCKD Study. 
 
Note: Please see Supplementary Table 2 for tabular presentation of results. 
 
